Search results for:
Mölnlycke® and Ondine Join Forces Against HAIs
Mölnlycke Health Care partners with Ondine for Steriwave distribution collaboration in the key markets of the UK, Europe and the Middle East Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, and Mölnlycke Health Care (Gothenburg Sweden), a world-leading MedTech company that specializes in innovative [...]
Steriwave in all British Columbia Health Authorities
Vancouver, British Columbia, Canada - August 23, 2024 Ondine Biomedical Inc. (LON: OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce that Steriwave® nasal decolonization is now being used in all five of British Columbia's health [...]
Leeds Teaching Hospitals NHS Trust to use Steriwave
Vancouver, British Columbia, Canada - August 6, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, and Iskus Health announce that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave® nasal decolonization technology later this month. Leeds Teaching [...]
Ondine CMO interviewed in European Biopharmaceutical Review
Ondine Biomedical's Chief Medical Officer, Simon Sinclair, has been interviewed for the Summer edition of European Biopharmaceutical Review about the risks of AMR and rising rates of hospital infections. Read the full interview here: Antimicrobial resistance and healthcare-associated infections: the current landscape and the future.
Steriwave now available through NHS Supply Chain
Vancouver, British Columbia, Canada - June 21, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, is pleased to announce that its Steriwave® nasal photodisinfection is now available through the NHS Supply Chain, making it significantly easier for NHS [...]
ECDC report shows HAIs are increasing antibiotic use
A third of microorganisms causing healthcare-associated infections were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patients Vancouver, British Columbia, Canada - May 10, 2024 A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore [...]
New study confirms nose is key source of infection
Findings include 86% of surgical site infections caused by bacteria from the patients’ own nose, skin, or gut and nearly 60% of infections are resistant to antibiotics Vancouver, British Columbia, Canada - April 25, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company [...]
Corporate and Trading Update
Significant revenue growth and commercial momentum Vancouver, British Columbia, Canada - April 24, 2024 Ondine Biomedical (LON: OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans. Commercial [...]
Steriwave in first Australian hospital
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical’s award-winning light-activated antimicrobial technology Vancouver, British Columbia, Canada - April 22, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North [...]
32% Fewer SSIs After Steriwave Replaced Mupirocin
New data shows reduced cardiac infections and significant cost savings after the light-activated antimicrobial, Steriwave, replaced the antibiotic standard of care at the Mazankowski Alberta Heart Institute Vancouver, British Columbia, Canada - April 15, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company [...]
For Media Information
Simon Vane Percy
Amanda Bernard
